For the quarter ending 2025-09-30, FBRX had -$12,730K decrease in cash & cash equivalents over the period. -$14,055K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -44,587 | - |
| Depreciation expense | 17 | 28 |
| Stock-based compensation expense | 1,479 | 3,115 |
| Net loss | - | -26,905 |
| Accretion of debt discount on available-for-sale securities | 6 | 240 |
| Prepaid expenses and other assets | 1,998 | -1,590 |
| Accounts payable | 558 | 488 |
| Accrued liabilities | 3,632 | 1,508 |
| Net cash used in operating activities | -14,000 | -20,416 |
| Purchase of property and equipment | 55 | 61 |
| Proceeds from redemptions of short-term investments | 0 | 36,350 |
| Net cash provided by (used in) investing activities | -55 | 36,289 |
| Proceeds from issuance of common stock and pre-funded warrants | 0 | 75,000 |
| Payment of issuance costs associated with financings | 475 | 6,966 |
| Proceeds from exercise of warrants | - | 2 |
| Proceeds from issuance of common stock upon exercise of underwriters' option | 1,779 | - |
| Proceeds from issuance of common stock under espp | 9 | 9 |
| Proceeds from exercise of warrants and options | 19 | - |
| Taxes paid related to net share settlement of equity awards | 5 | 18 |
| Settlement of fractional shares paid in cash | 0 | - |
| Net cash provided by (used in) financing activities | 1,325 | 68,027 |
| Net increase (decrease) in cash and cash equivalents | -12,730 | 83,900 |
| Cash and cash equivalents at beginning of period | 22,244 | - |
| Cash and cash equivalents at end of period | 93,414 | - |
Forte Biosciences, Inc. (FBRX)
Forte Biosciences, Inc. (FBRX)